News

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating...

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE,...

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ --...

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE,...

New generation of SOPHiA DDMTM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland, Sept. 4,...

SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD...

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland, Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland, Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland, July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year...

The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland, July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS...

The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /PRNewswire/ -- SOPHiA...

The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland , May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed BOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland , April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland , April 17, 2024...

The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland , April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

The Chile-based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland , April 2, 2024 /PRNewswire/ -- SOPHiA...

University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland , March 20, 2024

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland , March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:...

Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 BOSTON and ROLLE, Switzerland, March 05, 2024...

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /PRNewswire/ --...

The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland , Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS...

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland , Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized...

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology,...

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland , Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland , Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a...

World-class liquid biopsy testing will be available to SOPHiA GENETICS customers BOSTON and ROLLE, Switzerland , Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Through the expanded relationship CHU de Nîmes will advance its research of rare and inherited diseases through pharmacogenomics BOSTON and ROLLE, Switzerland , Nov. 30, 2023 /PRNewswire/ --...

Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft Azure to expand data-driven medicine capabilities while ensuring accuracy and security BOSTON and ROLLE, Switzerland , Nov....

The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and ROLLE, Switzerland , Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...

Record results on growth acceleration, significant improvement in operating loss and cash burn BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a...

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J., and ROLLE, Switzerland , Nov. 7, 2023...

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland , Oct. 18, 2023...

The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine BOSTON and ROLLE, Switzerland , Sept. 29, 2023 /PRNewswire

The SOPHiA DDM™ Platform will help Laboratorio Curie advance its research into BRCA gene mutations BOSTON and ROLLE, Switzerland , Sept. 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),...

With the help of the SOPHiA DDM™ Platform, IRST has introduced a new diagnostic kit that will support data- driven treatment planning for a dvanced ovarian cancer BOSTON and ROLLE, Switzerland ,...

The hospital is using the SOPHiA DDM™ Platform to advance the research of Homologous Recombinati on Repair Mutated Cancers BOSTON and ROLLE, Switzerland , Aug. 30, 2023 /PRNewswire/ -- SOPHiA...

Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer BOSTON and ROLLE, Switzerland , Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS...